MX2015000076A - Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario. - Google Patents

Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.

Info

Publication number
MX2015000076A
MX2015000076A MX2015000076A MX2015000076A MX2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A
Authority
MX
Mexico
Prior art keywords
secondary hyperparathyroidism
dihydroxyvitamin
methylene
treat secondary
treat
Prior art date
Application number
MX2015000076A
Other languages
English (en)
Spanish (es)
Inventor
Hector F Deluca
Margaret Clagett-Dame
Lori A Plum
Julia B Zella
Original Assignee
Wisconsin Alumni Reasearch Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015000076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Reasearch Foundation filed Critical Wisconsin Alumni Reasearch Foundation
Publication of MX2015000076A publication Critical patent/MX2015000076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2015000076A 2012-06-29 2013-03-14 Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario. MX2015000076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29
PCT/US2013/031574 WO2014003849A1 (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Publications (1)

Publication Number Publication Date
MX2015000076A true MX2015000076A (es) 2015-04-10

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000076A MX2015000076A (es) 2012-06-29 2013-03-14 Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.

Country Status (19)

Country Link
US (4) US9205096B2 (enExample)
EP (1) EP2866811A1 (enExample)
JP (1) JP2015522015A (enExample)
KR (1) KR20150030673A (enExample)
CN (1) CN104394871A (enExample)
AU (1) AU2013281217B2 (enExample)
BR (1) BR112014032847A2 (enExample)
CA (1) CA2877680C (enExample)
CL (1) CL2014003565A1 (enExample)
CO (1) CO7240358A2 (enExample)
HK (1) HK1206600A1 (enExample)
IL (1) IL236184A0 (enExample)
MX (1) MX2015000076A (enExample)
MY (1) MY172886A (enExample)
NZ (1) NZ703347A (enExample)
RU (1) RU2666995C2 (enExample)
SG (1) SG11201408731WA (enExample)
WO (1) WO2014003849A1 (enExample)
ZA (1) ZA201500119B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014032847A2 (pt) * 2012-06-29 2017-06-27 Wisconsin Alumni Res Found uso de 2-metileno-19-nor-(20s)-1alfa,25-dihidroxivilamina d3 para o tratamento de hiperparatiroidismo secundário
SG11201601692PA (en) * 2013-09-27 2016-04-28 Codexis Inc Structure based predictive modeling
CN105765592B (zh) 2013-09-27 2019-12-17 科德克希思公司 用于酶变体的自动筛选的方法、装置和系统
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) * 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
JP2003528833A (ja) 2000-03-27 2003-09-30 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 腎移植体安定化用のビタミンｄ化合物
CA2416194C (en) 2000-07-14 2009-10-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
CN1852718A (zh) * 2003-09-19 2006-10-25 辉瑞产品公司 用于治疗虚弱、肌肉损伤或少肌症的2－亚烷基－19－去甲－维生素d衍生物
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
AU2006213727B2 (en) 2005-02-11 2011-08-18 Wisconsin Alumni Research Foundation 2-methylene-19-nor- (20S-24S) - 1alpha, 25-dihydroxyvitamin-D2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
JP5908402B2 (ja) * 2009-08-03 2016-04-26 ウィスコンシン・アルムニ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 腎疾患の予防方法およびその症状を処置する方法
CA2794006C (en) 2010-03-23 2017-11-28 Wisconsin Alumni Research Foundation (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3
BR112014032847A2 (pt) * 2012-06-29 2017-06-27 Wisconsin Alumni Res Found uso de 2-metileno-19-nor-(20s)-1alfa,25-dihidroxivilamina d3 para o tratamento de hiperparatiroidismo secundário

Also Published As

Publication number Publication date
US20140005152A1 (en) 2014-01-02
EP2866811A1 (en) 2015-05-06
CN104394871A (zh) 2015-03-04
AU2013281217B2 (en) 2017-03-02
IL236184A0 (en) 2015-01-29
BR112014032847A2 (pt) 2017-06-27
RU2666995C2 (ru) 2018-09-13
RU2015102831A (ru) 2016-08-20
KR20150030673A (ko) 2015-03-20
ZA201500119B (en) 2017-11-29
CO7240358A2 (es) 2015-04-17
MY172886A (en) 2019-12-13
HK1206600A1 (en) 2016-01-15
SG11201408731WA (en) 2015-01-29
US20140187522A1 (en) 2014-07-03
AU2013281217A1 (en) 2015-01-22
US9717744B2 (en) 2017-08-01
US10046000B2 (en) 2018-08-14
NZ703347A (en) 2016-05-27
JP2015522015A (ja) 2015-08-03
CL2014003565A1 (es) 2015-08-28
US20170252360A1 (en) 2017-09-07
US20160136184A1 (en) 2016-05-19
CA2877680C (en) 2017-08-29
US9205096B2 (en) 2015-12-08
WO2014003849A1 (en) 2014-01-03
CA2877680A1 (en) 2014-01-03
US9034853B2 (en) 2015-05-19

Similar Documents

Publication Publication Date Title
MX2015000076A (es) Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.
MX2016006103A (es) Suplemento a base de teacrina y metodo de uso del mismo.
CR20140376A (es) Compuestos para tratar la atrofia muscular espinal
PH12015500525A1 (en) Formulations of enzalutamide
SG11201404704UA (en) Database system using batch-oriented computation
CA143935S (en) Reformer exercise apparatus
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
IN2014CN04014A (enExample)
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
MX2015014344A (es) Terapia contra el cancer.
BR112013008492A2 (pt) recipiente de revelador, dispositivo de revelação, cartucho de processo, dispositivo de formação de imagem, e método de reabastecimento de revelador
AR089320A1 (es) Cepa de lactobacillus mucosae
MX2014011838A (es) Uso de neuregulina para tratar lesion de nervio periferico.
CL2017002304A1 (es) Métodos para tratar enfermedades
CL2016001428A1 (es) Uso de una composicion con ejercicios cognitivos util para la prevencion o el tratamiento de un desarrollo cognitivo retrasado en los niños.
BR112014009760A8 (pt) análogos de ácido siálico
IN2015DN04070A (enExample)
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
BR112012024704A8 (pt) uso terapêutico de tetratiomolibdato.
EP3240549A4 (en) Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
ECSP17021138A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevención de la acumulación de grasa
MY164592A (en) Method for emulsion treatment
AR081220A1 (es) Uso de teriflunomida para el tratamiento de la atrofia cerebral